Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar.

ABSTRACT:

Background

Many patients with inflammatory bowel disease (IBD) have transitioned from an infliximab originator to a biosimilar. However, some patients retransition to the originator (i.e. stop biosimilar and reinitiate the originator). Whether this sign of potential unsatisfactory treatment response is specifically related to the infliximab biosimilar or the patient and/or the disease including patients' beliefs on the biosimilar is unclear.

Objectives

We aimed to compare the risk of and reasons for infliximab discontinuation between retransitioned patients and those remaining on biosimilar.

Design

Non-interventional, multicentre cohort study.

Methods

IBD patients who transitioned from infliximab originator to biosimilar between January 2015 and September 2019

SUBMITTER: Meijboom RW 

PROVIDER: S-EPMC10496466 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature